CR9114 clinical trials

A Phase 2a Randomized, Double-blind, Placebo-controlled Trial with Open-label Dose-finding Cohorts to Evaluate the Efficacy and Safety of CR9114 Monoclonal Antibody Administered as Intranasal Doses in Healthy Adult Participants who are Challenged with a Live, Wild-type Influenza Type A Virus (A/Belgium/4217/2015 H3N2)

This study is testing a new nose spray medicine called CR9114 for flu. Healthy adults will get a mild flu virus and then either the medicine or a dummy spray to see if it makes them less sick and how safe it is.